Effect of Core Stabilization Exercises and Neuromuscular Electrical Stimulation in Patients With Idiopathic Pulmonary Fibrosis

Sponsor
Istanbul University-Cerrahpasa (Other)
Overall Status
Unknown status
CT.gov ID
NCT04197791
Collaborator
(none)
36
1
2
11.7
3.1

Study Details

Study Description

Brief Summary

Interstitial lung disease (ILD) refers to various diseases that occur idiopathic or secondary to some causes, commonly affecting the lung parenchyma, and present with varying degrees of inflammation and fibrosis. Idiopathic pulmonary fibrosis (IPF) progressing with progressive shortness of breath causes a decrease in exercise capacity and quality of life, restrictive changes in pulmonary function tests and a decrease in diffusion capacity. It has been reported that core stabilization exercises improve respiratory function, respiratory muscle strength and functional capacity in healthy individuals and some disease groups. It has also been reported that neuromuscular electrical stimulation (NMES) applied to lower extremity, upper extremity and back or quadriceps muscles reduces dynamic hyperinflation and dyspnea during exercise and increases exercise capacity in COPD patients.No studies have been performed using core stabilization exercises and NMES in IPF patients. It can be assumed that this therapeutic intervention may also be useful in IPF.

Our study was planned to investigate the efficacy of core stabilization exercises and NMES in patients with IPF.

Condition or Disease Intervention/Treatment Phase
  • Device: Neuromuscular Electrical Stimulation
  • Other: Core Stabilization Exercises
N/A

Detailed Description

Stable idiopathic pulmonary fibrosis will be included in the study from the Istanbul Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital. Patients will be randomized into 2 groups; Neuromuscular Electrical Stimulation (NMES) and Core Stabilization Exercises Training Group (n: 18): 2 days per week for 6 weeks duration. The demographic measurements, respiratory function test, respiratory muscle strength, dyspnea, 6 minutes walking test, quality of life, depression and clinical characteristics and physical fitness of the patients will be recorded. The following parameters will be evaluated before and after the training of the patients in the two groups.

Study Design

Study Type:
Interventional
Actual Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Effect of Core Stabilization Exercises and Neuromuscular Electrical Stimulation (NMES) in Patients With Idiopathic Pulmonary Fibrosis (IPF) Randomized Controlled Trial
Actual Study Start Date :
Dec 10, 2019
Anticipated Primary Completion Date :
Nov 1, 2020
Anticipated Study Completion Date :
Dec 1, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Neuromuscular Electrical Stimulation (NMES)

Neuromuscular Electrical Stimulation will be applied to 18 patients with idiopathic pulmonary fibrosis. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.

Device: Neuromuscular Electrical Stimulation
Neuromuscular Electrical Stimulation(NMES) to core stabilization muscles will be applied using 8 electrodes. The application time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.

Experimental: Core Stabilization Exercises

Core stabilization exercises will be applied to 18 patients with idiopathic pulmonary fibrosis. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.

Other: Core Stabilization Exercises
Warm-up and cool-down exercises will be performed before and after core stabilization exercises. The exercise time will be 30 minutes. Treatment will be programmed for 2 days per week. The program will continue for 6 weeks.

Outcome Measures

Primary Outcome Measures

  1. Forced Vital Capacity (FVC) [Baseline and 6 weeks]

    Change from baseline Forced Vital Capacity (FVC) in respiratory function test at 6 weeks. FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.

  2. Forced Expiratory Volume 1 second (FEV1) [Baseline and 6 weeks]

    Change from baseline Forced Expiratory Volume 1 second (FEV1) in respiratory function . FEV1 will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.

  3. Forced Expiratory Volume 1 second / Forced Vital Capacity (FEV1 / FVC) [Baseline and 6 weeks]

    Change from baseline FEV1 / FVC in respiratory function test at 6 weeks. FEV1 / FVC will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.

  4. Forced Expiratory flow from between 25% to 75% of Vital Capacity (FEF 25-75) [Baseline and 6 weeks]

    Forced expiratory flow at 25-75% of FVC [FEF25-75] (L/sec) was measured with lung spirometry as it was described for FVC, FEV1, FEV1 / FVC measurements.

  5. Peak flow rate (PEF) [Baseline and 6 weeks]

    Change from baseline Peak flow rate (PEF) in respiratory function test at 6 weeks. PEF will be evaluated using spirometry, according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria.

  6. Single-breath Diffusing Capacity for Carbon Monoxide (DLCO) [Baseline and 6 weeks]

    The DLCO is a pulmonary function test that measures the capacity for the lung to carry out gas exchange between the inhaled breath and the pulmonary capillary blood vessels and the DLCO %-predicted represents the DLCO expressed as a percentage of the expected normal valued based on the participant's age, height, gender and ethnicity. The DLCO %-predicted is reduced in patients with interstitial lung disease and is used as a measure of disease severity.

  7. Functional capacity [Baseline and 6 weeks]

    Change from baseline functional capacity test at 6 weeks. Functional capacity will be assessed by the 6 minute walking test. The test will be performed according to American Thoracic Society (ATS) criteria. Patients will be allowed to rest for 10 minutes before the test. Heart rate, blood pressure, respiratory frequency, oxygen saturation, fatigue and dyspnea perception will be recorded before and after the test. Walking distance will be calculated.

Secondary Outcome Measures

  1. Maximum Inspiratory Pressure (MIP) [Baseline and 6 weeks]

    Change from baseline Maximum Inspiratory Pressure (MIP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MIP measurement is a non-invasive technique.

  2. Maximum Expiratory Pressure (MEP) [Baseline and 6 weeks]

    Change from baseline Maximum Expiratory Pressure (MEP) at 6 weeks. Respiratory muscle strength will be measured according to the portable, electronic intraoral pressure measuring device (MicroRPM, Micro Medical UK), American Thoracic Society (ATS) and European Respiratory Society (ERS) criteria. The most commonly used method for evaluating respiratory muscles is MEP measurement is a non-invasive technique.

  3. Physical Activity [Baseline and 6 weeks]

    Change from baseline physical activity scores at 6 weeks. International Physical Activity Questionnaire (IPAQ) - Short Form (Turkish version of scale ).This questionnaire assesses, in minutes, the physical activity performed by the volunteers during the period of one week. The IPAQ considered all activities carried out by the volunteer (e.g. leisure, sport, exercise, and activities at home or in the garden). According to the responses, the volunteer is considered very active, active, irregularly active or sedentary, according to the intensity and time of the exercises practiced over the last week.

  4. Change from baseline quality of life: King's Brief Interstitial Lung Disease Questionnaire (K-BILD) [Baseline and 6 weeks]

    Quality of life will be measured with King's Brief Interstitial Lung Disease Questionnaire (K-BILD). It is a 15-item validated questionnaire assessing health status in patients with an interstitial lung disease. Questions are related to three domains: breathlessness and activities, psychological aspects, and chest symptoms. Each question has 7 possible answers. The questionnaire has a scale from 0 - 100, in which 100 means highest quality of life.

  5. Change from baseline quality of life: Hospital Anxiety and Depression Scale (HADS) [Baseline and 6 weeks]

    Quality of life will be measured with the Hospital Anxiety and Depression Scale (HADS). It is a 14-item questionnaire, 7 items are related to depression and 7 items are related to anxiety. Each question has 4 different answer options, each scored from 0-3. Scores are summed up for each field (depression or anxiety) with 0 points as lowest possibility and 21 scores as highest (0-7 = normal, 8-10 = borderline abnormal, and 11-21 = abnormal).

  6. The Fatigue Severity Scale [Baseline and 6 weeks]

    The Fatigue Severity Scale is a self-administered questionnaire with 9 items (questions) investigating the severity of fatigue in different situations during the past week. Respondents answer using a Likert scale ranging from 1 to 7. ''1'' indicates strong disagreement with the statement, while ''7'' indicates strong agreement. Total score is calculated by deriving an arithmetic mean. FSS scores range from 0-63. A score of 36 or higher generally indicates severe fatigue.

  7. Timed up and go test [Baseline and 6 weeks]

    Functional mobility was measured with Timed up and go test [TUGT] (sec). The patient sitting on chair stood up with the instruction of physiotherapist and walked 3 meters as fast as possible, walked back to the chair and sat down again. The total duration was recorded in seconds. Lower time reflects better functional mobility. TUGT was performed with 3 repetitions.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Clinically stable

  • Having no infection or exacerbation in the last 3 months

  • Having no uncontrolled cardiological, psychological problems

  • Having no neoplasm, sarcoidosis or collagen vascular diseases

  • Having no neurological, inner ear or orthopedic disease

  • Patients who volunteered to study

Exclusion Criteria:
  • Over 75 years,

  • Chronic obstructive pulmonary disease (COPD)

  • Acute coronary artery disease,

  • Collagen vascular disease,

  • Pneumoconiosis,

  • Sarcoidosis,

  • Cancer

  • Non-parenchymal restrictive lung disease and other serious comorbid conditions,

  • Oxygen saturation in room air at rest <80%

  • During acute exacerbation,

  • Echocardiography RVSP> 50 mmHg

  • Patients taking more than 20mg corticosteroid per day

  • Contraindications to apply the neuromuscular electrical stimulation (pace maker, sensory defects, etc...)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital Istanbul Turkey

Sponsors and Collaborators

  • Istanbul University-Cerrahpasa

Investigators

  • Study Director: Rengin Demir, Prof, Istanbul University-Cerrahpasa

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
ELÇİN ÇAKIR, MSc student, Istanbul University-Cerrahpasa
ClinicalTrials.gov Identifier:
NCT04197791
Other Study ID Numbers:
  • 272303
First Posted:
Dec 13, 2019
Last Update Posted:
Dec 16, 2019
Last Verified:
Dec 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by ELÇİN ÇAKIR, MSc student, Istanbul University-Cerrahpasa
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 16, 2019